Enliven Therapeutics Statistics
Total Valuation
ELVN has a market cap or net worth of $835.53 million. The enterprise value is $522.09 million.
Important Dates
The next estimated earnings date is Tuesday, May 13, 2025, after market close.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ELVN has 49.00 million shares outstanding. The number of shares has increased by 32.43% in one year.
| Current Share Class | 49.00M |
| Shares Outstanding | 49.00M |
| Shares Change (YoY) | +32.43% |
| Shares Change (QoQ) | +3.30% |
| Owned by Insiders (%) | 5.46% |
| Owned by Institutions (%) | 63.54% |
| Float | 26.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.69 |
| P/TBV Ratio | 2.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 19.99
| Current Ratio | 19.99 |
| Quick Ratio | 19.69 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -32.04% and return on invested capital (ROIC) is -23.50%.
| Return on Equity (ROE) | -32.04% |
| Return on Assets (ROA) | -21.87% |
| Return on Invested Capital (ROIC) | -23.50% |
| Return on Capital Employed (ROCE) | -33.74% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.44M |
| Employee Count | 62 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ELVN has paid $232,000 in taxes.
| Income Tax | 232,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -19.12% in the last 52 weeks. The beta is 1.09, so ELVN's price volatility has been similar to the market average.
| Beta (5Y) | 1.09 |
| 52-Week Price Change | -19.12% |
| 50-Day Moving Average | 20.35 |
| 200-Day Moving Average | 23.25 |
| Relative Strength Index (RSI) | 41.25 |
| Average Volume (20 Days) | 358,501 |
Short Selling Information
The latest short interest is 7.27 million, so 14.83% of the outstanding shares have been sold short.
| Short Interest | 7.27M |
| Short Previous Month | 7.34M |
| Short % of Shares Out | 14.83% |
| Short % of Float | 26.98% |
| Short Ratio (days to cover) | 28.78 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -104.55M |
| Pretax Income | -79.60M |
| Net Income | -89.02M |
| EBITDA | -104.24M |
| EBIT | -104.55M |
| Earnings Per Share (EPS) | -$1.89 |
Full Income StatementBalance Sheet
The company has $313.44 million in cash and n/a in debt, giving a net cash position of $313.44 million or $6.40 per share.
| Cash & Cash Equivalents | 313.44M |
| Total Debt | n/a |
| Net Cash | 313.44M |
| Net Cash Per Share | $6.40 |
| Equity (Book Value) | 309.85M |
| Book Value Per Share | 6.33 |
| Working Capital | 302.21M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$73.19 million and capital expenditures -$44,000, giving a free cash flow of -$73.24 million.
| Operating Cash Flow | -73.19M |
| Capital Expenditures | -44,000 |
| Free Cash Flow | -73.24M |
| FCF Per Share | -$1.49 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |